Screener
Corvus Pharmaceuticals CRVS Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Property and equipment, net | 282 | 220 |
| Operating lease right-of-use asset | 751 | 839 |
| Investment in Angel Pharmaceuticals | 10,496 | 10,991 |
| Other assets | 1,720 | 855 |
| Total assets | $253,195 | $71,119 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,697 | $2,491 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's deferred tax assets and other non-current assets?
- Corvus Pharmaceuticals (CRVS) reported deferred tax assets and other non-current assets of $1.72M in Q1 2026.
- How has Corvus Pharmaceuticals's deferred tax assets and other non-current assets changed year-over-year?
- Corvus Pharmaceuticals's deferred tax assets and other non-current assets increased by 173.4% year-over-year, from $629K to $1.72M.
- What is the long-term trend for Corvus Pharmaceuticals's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's deferred tax assets and other non-current assets has grown at a 15.6% compound annual growth rate (CAGR), from $414K to $855K.
Ask your AI about Corvus Pharmaceuticals's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude